Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Craig-Hallum analyst Matt Hewitt maintains BioLife Solns (NASDAQ:BLFS) with a Buy and raises the price target from $23 to $30.
Northland Capital Markets analyst Carl Byrnes maintains BioLife Solns (NASDAQ:BLFS) with a Outperform and raises the price t...
Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to...
BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.14)...
TD Cowen analyst Steven Mah maintains BioLife Solns (NASDAQ:BLFS) with a Buy and raises the price target from $20 to $26.
Benchmark analyst Robert Wasserman upgrades BioLife Solns (NASDAQ:BLFS) from Hold to Buy and announces $25 price target.
2024 Revenue GuidanceBioLife Solutions is affirming its 2024 revenue guidance of $95.5 million to $100.0 million. This is based...
BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.28)...
